Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
Natural killer/T-cell lymphoma (NKTCL) patients with relapsed/refractory disease had very
poor outcome. Anti-PD-1 antibody showed promising results in response, but but the complete
remission rate of was low. Some anti-PD-1 antibody based regimen showed higher and deeper
response in NKTCL patients.
Phase:
N/A
Details
Lead Sponsor:
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine